文献速递创伤与烧伤呼吸衰竭与机械通气重症综合管理与镇静镇痛

多发性肋骨骨折患者无创通气与经鼻高流量氧疗的成本效果与临床结局比较

Cost-effectiveness and clinical outcomes comparison between noninvasive ventilation and high-flow nasal cannula use in patients with multiple rib fractures.
PubMed 文献 · J Trauma Acute Care Surg · 2025-04-15
一句话结论多发性肋骨骨折患者中,无创通气较经鼻高流量氧疗死亡率和气管切开率更低、住院更短、费用更低,无创通气具有成本效果优势。

该回顾性队列研究利用2020—2021年美国全国住院患者样本数据库,纳入18—89岁、两根及以上肋骨骨折且未先行气管插管的成人创伤患者,比较无创通气与经鼻高流量氧疗的临床结局与成本效果。经逆概率治疗加权调整后,无创通气组死亡率11.4% vs 经鼻高流量氧疗组17.0%(p=0.007)、气管切开率1.2% vs 3.1%(p=0.006)均更低,肺部并发症更少;插管率12.0% vs 15.6%(p=0.085)无统计学差异。经鼻高流量氧疗组住院时间更长(13天 vs 10天,p<0.001)、总费用更高(42,505美元 vs 32,024美元,p<0.001)。成本效果分析显示无创通气以更低成本获得更好结局,占优经鼻高流量氧疗。

要点

  • 多发性肋骨骨折未插管成人患者中,无创通气组死亡率11.4% vs 经鼻高流量氧疗组17.0%(p=0.007),无创通气更低。
  • 无创通气组气管切开率1.2% vs 经鼻高流量氧疗组3.1%(p=0.006),无创通气更低且肺部并发症更少。
  • 两组插管率12.0% vs 15.6%(p=0.085)无统计学差异。
  • 经鼻高流量氧疗组住院时间13天 vs 无创通气组10天(p<0.001),总费用42,505美元 vs 32,024美元(p<0.001)。
  • 成本效果分析以避免插管为效果指标、支付意愿阈值50,000美元/效果单位,无创通气占优经鼻高流量氧疗。

适用人群与场景

  • 2020—2021年美国全国住院患者样本数据库中18—89岁成人创伤患者,两根及以上肋骨骨折,接受无创通气或经鼻高流量氧疗且未先行气管插管。
  • 排除其他部位严重损伤(简明损伤定级评分≥3)或24小时内死亡者,以聚焦孤立性胸部损伤。

研究设计与关键结果

  • 回顾性队列研究,使用2020—2021年美国全国住院患者样本数据库,纳入18—89岁两根及以上肋骨骨折且未先行气管插管的成人创伤患者,比较无创通气与经鼻高流量氧疗,采用逆概率治疗加权平衡人口学、合并症与损伤严重度。
  • 主要结局:无创通气组死亡率11.4% vs 经鼻高流量氧疗组17.0%(p=0.007),气管切开率1.2% vs 3.1%(p=0.006),无创通气组肺部并发症更少。
  • 插管率无创通气组12.0% vs 经鼻高流量氧疗组15.6%(p=0.085),无统计学差异。
  • 经鼻高流量氧疗组住院时间13天 vs 无创通气组10天(p<0.001),总费用42,505美元 vs 32,024美元(p<0.001)。
  • 成本效果分析以避免插管为效果指标、支付意愿阈值50,000美元/效果单位,无创通气占优经鼻高流量氧疗(以更低成本获得更好结局)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究;证据等级:治疗/照护管理,Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在多发性肋骨骨折患者中,无创通气可能较经鼻高流量氧疗是更具成本效果和临床优势的选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with multiple rib fractures often require advanced respiratory support to prevent intubation and associated morbidity. Noninvasive ventilation (NIV) and high-flow nasal cannula (HFNC) are commonly used, but direct comparisons of clinical outcomes and cost-effectiveness remain limited. This study aimed to compare NIV versus HFNC using a large, nationwide US database.

METHODS: This retrospective cohort study used the 2020-2021 National Inpatient Sample database to identify adult trauma patients (18-89 years) with two or more rib fractures who received either NIV or HFNC without prior intubation. To focus on isolated thoracic injuries, patients with significant injuries elsewhere (Abbreviated Injury Scale score ≥3) or who died within 24 hours were excluded. Inverse probability of treatment of weighting was used to balance patient characteristics, including demographics, comorbidities, and injury severity. Primary outcomes included mortality, tracheostomy, pulmonary complications, and intubation rates. Hospital length of stay and total costs were also assessed. Cost-effectiveness analyses were conducted with intubation avoidance as the effectiveness measure, and a willingness-to-pay threshold of US $50,000 per effectiveness unit was used.

RESULTS: After adjustment, the NIV group demonstrated significantly better outcomes compared with HFNC, including lower mortality (11.4% vs. 17.0%, p = 0.007) and tracheostomy (1.2% vs. 3.1%, p = 0.006), and fewer pulmonary complications. Although intubation rates were not statistically different (12.0% vs. 15.6%, p = 0.085), the HFNC group had longer length of stay (13 vs. 10 days, p < 0.001) and incurred higher costs (US $42,505 vs. US $32,024, p < 0.001). Cost-effectiveness analysis revealed that NIV dominated HFNC, yielding better outcomes at lower costs.

CONCLUSION: Among patients with multiple rib fractures, NIV yielded superior clinical outcomes, shortened hospital stays, and reduced costs compared with HFNC. These findings suggest that NIV may be a more cost-effective and clinically advantageous choice.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Kwon J, Allison-Aipa T, Patton T, et al. Cost-effectiveness and clinical outcomes comparison between noninvasive ventilation and high-flow nasal cannula use in patients with multiple rib fractures. J Trauma Acute Care Surg. 2025. PMID: 40232169. doi:10.1097/TA.0000000000004629

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。